Zero Minis - Acceptability and Tolerance Market Research
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
- 主要终点
- Daily compliance
研究概览
简要总结
The purpose of this prospective, observational study is to evaluate the tolerability and acceptability of Zero minis, a range of protein substitute tablets for use in the dietary management of children with either TYROSINAEMIA Type I, II, III or ALKAPTONURIA, HOMOCYSTINURIA, or MAPLE SYRUP URINE DISEASE (MSUD) over the age of 7 years.
详细描述
The principle treatment for children with inborn amino acid disorders is a strict low protein diet. Part of this treatment requires the administration of a protein substitute in order to meet basic protein requirements for normal growth and development. Several brands of protein substitutes for inborn amino acid disorders are already available in various presentations. However, compliance with taking protein substitutes continues to be a challenge. As a low protein diet is usually recommended for life, long term compliance is always a major concern. As a result, improving the choice in terms of product type may aid compliance.
Zero minis are a range of protein substitute tablets specifically designed for use in the dietary management of rare amino acid disorders like Tyrosinaemia type I, II, III or Alkaptonuria, Homocystinuria, and MSUD in children from ≥3 years of age onwards. Zero minis are concentrated protein substitutes containing a mixture of pure amino acids (except the amino acid(s) which can´t be metabolized) enriched with vitamins, minerals and trace elements. It is anticipated that they will be a suitable alternative choice for patients with rare metabolic disorders including: tyrosinaemia type I, II, III or alkaptonuria, homocystinuria, or MSUD, broadening the variety of protein substitutes they can choose from in order to suit their lifestyle and preferences.
This is a prospective, multicentre, observational tolerance study with 15 children with rare metabolic disorders. Subjects who are currently taking a protein substitute for the dietary management of either tyrosinaemia type I, II, III or alkaptonuria, homocystinuria, or MSUD, will be recruited for a 7-day trial taking the new ready-to-use protein substitute tablets to evaluate the tolerability and acceptability of the study products. Subjects will replace some or all of their usual protein substitute with the new product suitable for their diagnosed rare metabolic disease.
During the 7-day trial subjects or caregivers will be asked to complete a daily questionnaire recording information on:
- Usage and compliance
- Ease of use and any issues with administration
- Any gastro-intestinal side-effects.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 7 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Tyrosinaemia type I, II III or Alkaptonuria requiring a tyrosine- and phenylalanine-free protein substitute.
- •Diagnosis of Homocystinuria requiring a methionine-free, cystine-enriched protein substitute.
- •Diagnosis of MSUD requiring a valine-, leucine- and isoleucine-free protein substitute.
- •Subjects who are already taking a protein substitute for one of the specified rare metabolic disorders and are willing to try the study product for 7 days.
- •Children aged 7 years and over.
- •Written informed consent obtained from parental caregiver.
排除标准
- •Presence of serious concurrent illness
- •Lead Dietitian's uncertainty about the willingness or ability of the patient to comply with the protocol requirements
- •Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
- •Any children having taken antibiotics over the previous 2 weeks leading up to the study.
- •Children less than 7 years of age.
结局指标
主要结局
Daily compliance
时间窗: 7 days
Compliance, with currently prescribed protein substitute will be assessed at the beginning of the 7-days trial. Usage and compliance with the study product will subsequently assessed daily from days 1-7 using standardised questionnaires, where patients document the the amount of consumed study product vs the prescribed doses.
次要结局
- Patient Acceptability(7 days)
- Treatment-Emergent tolerability(7 days)
- Metabolic control(7 days)
- Incidence of study product emergent events.(7 days)